Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer-Reference-Cited by-同舟云学术

Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer

Published:2002-06 Issue:6 Volume:9 Page:359-361
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J Urol

Author:

Kinouchi Toshiaki,Maeda Osamu,Ono Yutaka,Meguro Norio,Kuroda Masao,Usami Michiyuki

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1442-2042.2002.00476.x/fullpdf

Reference6 articles.

1. LHRH Analogue as a Depot Preparation (Zoladex) in the Treatment of Advanced Carcinoma of the Prostate Followed by Orchiectomy as a Second Line Therapy—A Phase II Study

2. Idiopathic Resistance to Luteinizing Hormone-Releasing Hormone Analogue in a Patient with Prostatic Carcinoma

3. GONADOTROPIN RELEASING HORMONE ANALOGUE ANTIANDROGEN FAILURE SECONDARY TO A PITUITARY ADENOMA

4. FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHM

5. Prostate-specific antigen—all that rises is not refractory

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer;Anti-Cancer Drugs;2020-08-17

2. Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy;Prostate International;2015-12

3. Response to degarelix after resistance to luteinizing hormone–releasing hormone agonist therapy for metastatic prostate cancer;Anti-Cancer Drugs;2011-03

4. Will GnRH antagonists improve prostate cancer treatment?;Trends in Endocrinology & Metabolism;2009-01

5. Androgen Deprivation by Activating the Liver X Receptor;Endocrinology;2008-05-01